{{Rsnum
|rsid=2295490
|Gene=TRIB3
|Chromosome=20
|position=388261
|Orientation=plus
|ReferenceAllele=A
|MissenseAllele=G
|GMAF=0.1552
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=TRIB3
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 76.8 | 20.5 | 2.7
| HCB | 59.7 | 35.8 | 4.5
| JPT | 55.8 | 38.9 | 5.3
| YRI | 73.3 | 24.0 | 2.7
| ASW | 71.9 | 28.1 | 0.0
| CHB | 59.7 | 35.8 | 4.5
| CHD | 70.6 | 26.6 | 2.8
| GIH | 39.4 | 48.5 | 12.1
| LWK | 68.2 | 29.1 | 2.7
| MEX | 91.4 | 8.6 | 0.0
| MKK | 57.7 | 37.8 | 4.5
| TSI | 70.3 | 28.7 | 1.0
| HapMapRevision=28
}}[[rs2295490]] is a SNP in the tribbles homolog 3 [[TRIB3]] gene, also known as Q84R. The (A) allele encodes the Gln (Q), while the (G) allele encodes the Arg (R).

A study involving four different case-control samples comprising a total of 5469 Caucasisans determined that [[rs2295490]](G) was nominally associated with [[type-2 diabetes]] (odds ratio 1.17, CI: 1.00-1.36, p = 0.04). When stratified by age of diabetes onset, these carriers had an increased risk of early-onset T2D (OR 1.32, CI: 1.10-1.58, p = 0.002).{{PMID|18984671|OA=1
}}

{{PMID|19139803}} this gain of function mutation may affect insulin signaling and increase the risk of insulin resistance

{{PharmGKB
|RSID=rs2295490
|Name_s=TRIB3: Q84R
|Gene_s=TRIB3
|Feature=
|Evidence=PubMed ID:18984671
|Annotation=This variant in the TRIB3 gene is associated with early-onset T2D in Whites. This Q84R "gain of function" polymorphism, impairs insulin signaling.
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA162363984
}}

{{PMID Auto
|PMID=20393693
|Title=TRIB3 R84 variant affects glucose homeostasis by altering the interplay between insulin sensitivity and secretion
}}
{{PMID Auto
|PMID=20592469
|Title=The pseudokinase tribbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse beta cells
|OA=1
}}

{{GET Evidence
|gene=TRIB3
|aa_change=Gln84Arg
|aa_change_short=Q84R
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2295490
|overall_frequency_n=1682
|overall_frequency_d=10756
|overall_frequency=0.156378
|n_genomes=10
|n_genomes_annotated=0
|n_haplomes=11
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|nblosum100=0
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23633196
|Title=Joint effect of insulin signaling genes on insulin secretion and glucose homeostasis
}}

{{PMID Auto
|PMID=23107043
|Title=Joint effect of insulin signaling genes on cardiovascular events and on whole body and endothelial insulin resistance.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}